Patents by Inventor Olli Laitinen
Olli Laitinen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240090851Abstract: Various methods and systems are provided for monitoring and displaying a patient status. In one example, the patient monitoring system includes a display device configured to display a patient status view include on or more multidimensional plots overlaying more than one of real time values, historical values, and upper and lower threshold values for a plurality of patient parameters, and additionally being configured to display an abbreviated representation of the one or more multidimensional plots that can be reached directly from the patient status view. The abbreviated representation is displayed in an unlaunched state, and displays a limited version of the respective multidimensional plot and is selectable to launch and enable the respective multidimensional plot to be seen.Type: ApplicationFiled: September 15, 2022Publication date: March 21, 2024Inventors: Mika Olli Kristian Särkelä, Helena Liisa Anneli Aito, Matti Juhani Laitinen, Milvi Kristiina Soosalu, Virpi Kristiina Lahdenmäki
-
Patent number: 11911456Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: GrantFiled: April 7, 2021Date of Patent: February 27, 2024Assignee: Vactech OyInventors: Heikki Hyöty, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Publication number: 20240024231Abstract: The present invention relates to a hydrogel material hydrogel material, comprising a first hydrogel comprising 0.15-21 wt-% of a functionalised triblock molecule having a formula (1) wherein n is 4-680 and m is 1-10, based on a total weight of the first hydrogel. The first hydrogel further comprises 0.85-3.3 wt-% of silica, based on the total weight of the first hydrogel, and 75-99 wt-% of an aqueous liquid, based on the total weight of the first hydrogel. The —Si—OH groups of the silica form a —Si—O—Si— bond with the —Si—(O)3— group of the functionalised triblock molecule of formula (1).Type: ApplicationFiled: September 29, 2021Publication date: January 25, 2024Inventors: Mika Jokinen, Alar Kaljukivi, Ari Rosling, Tatu Assmuth, Vesna Blazevic, Vesa Hytönen, Olli Laitinen, Suvi Heinimäki
-
Patent number: 11633468Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: GrantFiled: August 17, 2020Date of Patent: April 25, 2023Assignee: Vactech OyInventors: Hyöty Heikki, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Publication number: 20210220465Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: ApplicationFiled: April 7, 2021Publication date: July 22, 2021Inventors: Heikki Hyöty, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Publication number: 20210023196Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: ApplicationFiled: August 17, 2020Publication date: January 28, 2021Inventors: Hyöty Heikki, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Patent number: 10780157Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: GrantFiled: February 1, 2019Date of Patent: September 22, 2020Assignee: Vactech OyInventors: Hyöty Heikki, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Patent number: 10675344Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: GrantFiled: February 1, 2019Date of Patent: June 9, 2020Assignee: Vactech 0yInventors: Hyöty Heikki, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Publication number: 20200000908Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: ApplicationFiled: February 1, 2019Publication date: January 2, 2020Inventors: Hyöty Heikki, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Publication number: 20190209675Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: ApplicationFiled: February 1, 2019Publication date: July 11, 2019Inventors: Hyöty Heikki, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Patent number: 10258685Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: GrantFiled: March 22, 2017Date of Patent: April 16, 2019Assignee: Vactech OyInventors: Hyöty Heikki, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Publication number: 20170281748Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: ApplicationFiled: March 22, 2017Publication date: October 5, 2017Inventors: Hyöty Heikki, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Publication number: 20140255425Abstract: The invention is directed to a vaccine comprising: i) coxsackie B virus CBV1 and CBV2, and ii) at least one coxsackie B virus selected from CBV3, CBV4, CBV5 and CBV6. The CBVs are present in the vaccine in inactivated form, in the form of a component of the virus or as an antibody against the virus. The vaccine is effective in preventing and treating type 1 diabetes. So is an anti-coxsackie B virus composition provided.Type: ApplicationFiled: October 18, 2012Publication date: September 11, 2014Inventors: Heikki Hyöty, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valérie Lecouturier, Jeffrey Almond, Malin Flodström-Tullberg
-
Publication number: 20130101992Abstract: There is an association between enteroviruses and type 1 diabetes (T1D). The present invention is based on the finding that particular enterovirus serotypes are T1D risk serotypes, while others are protective against the disease. The present invention relates to a diagnostic assay for type 1 diabetes (T1D), and especially to an assay for predicting the risk of contracting the disease. It also relates to a method of monitoring the efficacy of antiviral treatments aiming at prevention of T1D. The invention still further relates to a diagnostic kit.Type: ApplicationFiled: June 30, 2011Publication date: April 25, 2013Applicant: Vactech OYInventors: Heikki Hyoty, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valerie Lecouturier, Jeffrey Almond
-
Publication number: 20120003240Abstract: Coxsackie B virus CBV1 has been found to be strongly associated with the risk of contracting type 1 diabetes. A vaccine comprising CBV1, a component thereof or an antibody thereto is provided for use in preventing or treating type 1 diabetes. In addition CBV2 was also found to be diabetogenic.Type: ApplicationFiled: June 30, 2011Publication date: January 5, 2012Applicants: VACTECH OY, SANOFI PASTEURInventors: Heikki Hyoty, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valerie Lecouturier, Jeffrey Almond, Malin Flodstrom-Tullberg
-
Publication number: 20120003238Abstract: Some coxsackie B viruses have been found to have a protective effect on type 1 diabetes, while others increase the risk of the disease. This opens up new therapeutic implications in the form of vaccines. The protective viruses CBV3, CBV4, CBV5 and CBV6 may be used in live attenuated vaccines for preventing or treating type 1 diabetes. They may also be used for inducing an immune response against risk viruses like CBV1, and for eliminating the diabetogenic effect of the risk viruses. Type 1 diabetes may be prevented especially by vaccinating with live attenuated protective viruses CBV3, CBV4, CVB5 and CBV6, and further with inactivated diabetogenic/risk virus CBV1, components thereof or antibodies thereto.Type: ApplicationFiled: June 30, 2011Publication date: January 5, 2012Applicants: VACTECH OY, SANOFI PASTEURInventors: Heikki Hyoty, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valerie Lecouturier, Jeffrey Almond
-
Publication number: 20120003239Abstract: New enteroviruses associated with type 1 diabetes have been found, which opens up new therapeutic and diagnostic implications. A vaccine against at least one enterovirus selected from coxsackie A virus CAV4, CAV5, CAVE and echovirus 18 is provided for use in preventing or treating type 1 diabetes. A diagnostic assay for predicting the risk of contracting type 1 diabetes based on the determination of said enteroviruses is also provided.Type: ApplicationFiled: June 30, 2011Publication date: January 5, 2012Applicants: VACTECH OY, SANOFI PASTEURInventors: Heikki Hyoty, Mikael Knip, Olli Laitinen, Outi Tolonen, Minna Pulkki, Sami Oikarinen, Hanna-Riikka Honkanen, Valerie Lecouturier, Jeffrey Almond
-
Publication number: 20090011509Abstract: In a method of targeting intergration of a transgene comprising retrovirus-like DNA into a eukaryotic genome, the genome is cleared by an endonuclease and the transgene is introduced at the site of cleavage, wherein the endonuclease is specific to a site in an abundant rDNA locus and is fused to an integrase that mediates the introduction of the transgene. The fusion protein may be new.Type: ApplicationFiled: January 14, 2005Publication date: January 8, 2009Applicant: ARK THERAPEUTICS LTD.Inventors: Mervi Ahlroth, Diana Schenkwein, Kari Airenne, Seppo Yla-Herttuala, Olli Laitinen
-
Publication number: 20080280783Abstract: A nucleotide molecule comprising a selectable gene flanked by anL1 and anL2 attachment sites of a bacteriophage and additionally comprising an origin of replication. This can be used to create a baculovirus-based gene library.Type: ApplicationFiled: November 3, 2005Publication date: November 13, 2008Inventors: Kari Juhani Airenne, Seppo Yla-Herttuala, Olli Laitinen
-
Publication number: 20060172387Abstract: The present invention relates to new chimeric mutants of avidin protein with improved properties, e.g. thermostability, better stability against proteolysis, better charge properties (for example lower pl) compared to native avidin and avidin-related proteins, AVRs. The chimeric avidin mutants comprise mutants where a region or regions in avidin are substituted by a corresponding region or regions from an AVR protein.Type: ApplicationFiled: December 29, 2005Publication date: August 3, 2006Applicant: LICENTIA, LTD.Inventors: Vesa Hytonen, Olli Laitinen, Henri Nordlund, Markku Kulomaa